Everolimus medical insurance reimbursement policy inquiry

Everolimus (Everolimus)As a mTOR-targeted drug, it has been approved for multiple indications in China and has been included in the national medical insurance directory. For many patients, how to accurately understand local medical insurance reimbursement policies, prices of different specifications of drugs, and reimbursement restrictions is an important step in achieving long-term standardized treatment. As the implementation details of each province are constantly updated, the everolimus medical insurance policy presents the characteristics of "national unified catalog + local detailed rules implemented". Patients need to confirm with the documents issued by the local medical insurance bureau when seeking medical treatment. The current common clinical specifications are 2.5mg*30 tablets and 5mg*30 tablets. The market price is generally around 3,000 yuan, but the actual out-of-pocket ratio after medical insurance payment changes step by step due to regional differences.

According to the latest medical insurance directory, the reimbursement conditions for everolimus cover multiple solid tumors and some rare diseases, including: advanced renal cell carcinoma that has failed treatment with sunitinib or sorafenib, locally advanced or metastatic pancreatic neuroendocrine tumors, and non-functional gastrointestinal tract and neuroendocrine tumors of pulmonary origin, tuberous sclerosis-associated subependymal giant cell astrocytoma (SEGA), tuberous sclerosis-associated renal angiomyolipoma (TSC-AML), and postmenopausal patients after failure of hormone therapy HR-positive, HER2-negative advanced breast cancer and other groups. Each indication has clear clinical use restrictions in the medical insurance catalog. Doctors will generally judge whether it meets the reimbursement conditions based on medical records, pathology reports, imaging evidence and past medication history.

Generally speaking, before using everolimus, patients should proactively confirm with their attending doctor whether their condition is within the scope of medical insurance restrictions, and understand in advance the actual implementation details such as local medical insurance reimbursement ratios, whether dual channels are supported, and whether there are annual quota restrictions, so as to better plan the financial burden of long-term treatment. Keeping abreast of the latest medical insurance policies can not only reduce unnecessary financial expenses, but also help ensure continuity of treatment.

Reference materials:https://www.drugs.com/everolimus.html